Abbott Laboratories Asset Resilience Ratio
Abbott Laboratories asset resilience ratio. Abbott Laboratories (ABT) has an Asset Resilience Ratio of 9.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Abbott Laboratories defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Abbott Laboratories (1993–2024)
Asset resilience ratio of Abbott Laboratories from 1993 to 2024. This chart shows how Abbott Laboratories's Asset Resilience Ratio has changed over time. Read total liabilities of Abbott Laboratories for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Abbott Laboratories's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ABT current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $7.51 Billion | 8.92% |
| Short-term Investments | $222.00 Million | 0.26% |
| Total Liquid Assets | $7.73 Billion | 9.19% |
Asset Resilience Insights
- Limited Liquidity: Abbott Laboratories maintains only 9.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Abbott Laboratories Industry Peers by Asset Resilience Ratio
Compare Abbott Laboratories's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
T&L Co. Ltd
KQ:340570 |
Medical Devices | 26.03% |
|
Paxman AB
ST:PAX |
Medical Devices | -3.83% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.48% |
|
Pulsenmore Ltd
TA:PULS |
Medical Devices | 51.61% |
|
Geratherm Medical AG
XETRA:GME |
Medical Devices | 34.89% |
Abbott Laboratories Asset Resilience Ratio by Year (1993–2024)
Abbott Laboratories asset resilience ratio by year from 1993 to 2024. The table below shows the annual Asset Resilience Ratio data for Abbott Laboratories.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.79% | $7.97 Billion | $81.41 Billion | -0.16pp |
| 2023-12-31 | 9.94% | $7.28 Billion | $73.21 Billion | -3.72pp |
| 2022-12-31 | 13.66% | $10.17 Billion | $74.44 Billion | +0.03pp |
| 2021-12-31 | 13.63% | $10.25 Billion | $75.20 Billion | +3.78pp |
| 2020-12-31 | 9.85% | $7.15 Billion | $72.55 Billion | +3.75pp |
| 2019-12-31 | 6.10% | $4.14 Billion | $67.89 Billion | +0.02pp |
| 2018-12-31 | 6.08% | $4.09 Billion | $67.17 Billion | -6.52pp |
| 2017-12-31 | 12.60% | $9.61 Billion | $76.25 Billion | -21.53pp |
| 2016-12-31 | 34.13% | $18.77 Billion | $55.01 Billion | +31.58pp |
| 2015-12-31 | 2.55% | $1.12 Billion | $44.00 Billion | +1.65pp |
| 2014-12-31 | 0.91% | $397.00 Million | $43.79 Billion | -9.86pp |
| 2013-12-31 | 10.76% | $4.62 Billion | $42.95 Billion | +4.26pp |
| 2012-12-31 | 6.50% | $4.37 Billion | $67.23 Billion | +4.37pp |
| 2011-12-31 | 2.13% | $1.28 Billion | $60.28 Billion | -0.85pp |
| 2010-12-31 | 2.98% | $1.80 Billion | $60.57 Billion | +0.84pp |
| 2009-12-31 | 2.14% | $1.12 Billion | $52.58 Billion | -0.15pp |
| 2008-12-31 | 2.28% | $967.60 Million | $42.42 Billion | +1.36pp |
| 2007-12-31 | 0.92% | $364.44 Million | $39.71 Billion | -1.44pp |
| 2006-12-31 | 2.36% | $852.24 Million | $36.18 Billion | +2.14pp |
| 2005-12-31 | 0.21% | $62.41 Million | $29.14 Billion | -2.68pp |
| 2004-12-31 | 2.90% | $833.33 Million | $28.77 Billion | +1.81pp |
| 2003-12-31 | 1.09% | $291.30 Million | $26.72 Billion | +0.01pp |
| 2002-12-31 | 1.08% | $261.68 Million | $24.26 Billion | +0.84pp |
| 2001-12-31 | 0.24% | $56.16 Million | $23.30 Billion | -1.35pp |
| 2000-12-31 | 1.59% | $242.50 Million | $15.28 Billion | +0.79pp |
| 1999-12-31 | 0.80% | $115.20 Million | $14.47 Billion | +0.23pp |
| 1998-12-31 | 0.57% | $75.09 Million | $13.22 Billion | +0.33pp |
| 1997-12-31 | 0.24% | $28.99 Million | $12.06 Billion | +0.12pp |
| 1996-12-31 | 0.12% | $12.88 Million | $11.13 Billion | -0.25pp |
| 1995-12-31 | 0.37% | $34.50 Million | $9.41 Billion | +0.07pp |
| 1994-12-31 | 0.29% | $25.06 Million | $8.52 Billion | -0.72pp |
| 1993-12-31 | 1.02% | $78.15 Million | $7.69 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more